InterCure (INCR) Competitors $1.74 +0.03 (+1.75%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends INCR vs. DSGN, ITOS, ACB, QURE, URGN, RZLT, PRQR, ACIU, GNFT, and STROShould you be buying InterCure stock or one of its competitors? The main competitors of InterCure include Design Therapeutics (DSGN), iTeos Therapeutics (ITOS), Aurora Cannabis (ACB), uniQure (QURE), UroGen Pharma (URGN), Rezolute (RZLT), ProQR Therapeutics (PRQR), AC Immune (ACIU), Genfit (GNFT), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry. InterCure vs. Design Therapeutics iTeos Therapeutics Aurora Cannabis uniQure UroGen Pharma Rezolute ProQR Therapeutics AC Immune Genfit Sutro Biopharma Design Therapeutics (NASDAQ:DSGN) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking. Do analysts rate DSGN or INCR? Design Therapeutics currently has a consensus target price of $7.00, suggesting a potential upside of 34.62%. Given Design Therapeutics' higher probable upside, analysts clearly believe Design Therapeutics is more favorable than InterCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has preferable earnings and valuation, DSGN or INCR? InterCure has higher revenue and earnings than Design Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDesign TherapeuticsN/AN/A-$66.86M-$0.90-5.78InterCure$96.61M0.82-$16.83MN/AN/A Does the media favor DSGN or INCR? In the previous week, InterCure had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 1 mentions for InterCure and 0 mentions for Design Therapeutics. InterCure's average media sentiment score of 1.85 beat Design Therapeutics' score of 0.00 indicating that InterCure is being referred to more favorably in the news media. Company Overall Sentiment Design Therapeutics Neutral InterCure Very Positive Do insiders and institutionals have more ownership in DSGN or INCR? 56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 31.2% of Design Therapeutics shares are owned by company insiders. Comparatively, 0.2% of InterCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in DSGN or INCR? Design Therapeutics received 7 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote. CompanyUnderperformOutperformDesign TherapeuticsOutperform Votes1033.33% Underperform Votes2066.67% InterCureOutperform Votes3100.00% Underperform VotesNo Votes Which has more risk & volatility, DSGN or INCR? Design Therapeutics has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Is DSGN or INCR more profitable? InterCure's return on equity of 0.00% beat Design Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Design TherapeuticsN/A -18.48% -17.76% InterCure N/A N/A N/A SummaryInterCure beats Design Therapeutics on 7 of the 13 factors compared between the two stocks. Ad Opportunistic TraderMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicted the 2020 crash a month before it happened...For a limited time, he's revealing his latest forecast here. Get InterCure News Delivered to You Automatically Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCR vs. The Competition Export to ExcelMetricInterCurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$79.52M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.93115.5615.18Price / Sales0.82381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book0.645.324.665.02Net Income-$16.83M$153.56M$119.06M$225.46M7 Day Performance2.65%0.11%0.80%0.37%1 Month Performance-4.12%15.22%5.65%3.57%1 Year Performance63.08%41.14%36.76%29.44% InterCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCRInterCure1.2436 of 5 stars$1.75+1.7%N/A+72.3%$79.52M$96.61M0.00350Short Interest ↓Positive NewsDSGNDesign Therapeutics1.3973 of 5 stars$5.57+3.0%$7.00+25.7%+157.4%$315.38MN/A-6.1940Positive NewsITOSiTeos Therapeutics2.3392 of 5 stars$8.59+0.1%$30.50+255.1%-11.1%$313.72M$35M-2.8690Upcoming EarningsACBAurora Cannabis0.7124 of 5 stars$5.68-3.7%N/A+22.3%$309.82M$278.98M-8.111,073Upcoming EarningsQUREuniQure2.086 of 5 stars$6.31-1.9%$19.50+209.3%+1.7%$307.05M$15.84M-1.06500Upcoming EarningsURGNUroGen Pharma3.9724 of 5 stars$13.02+6.3%$48.38+271.5%+7.4%$305.37M$85.01M-3.97200Upcoming EarningsRZLTRezolute3.8153 of 5 stars$5.44-4.2%$11.57+112.7%+436.6%$304.25MN/A-4.0940News CoveragePRQRProQR Therapeutics2.8802 of 5 stars$3.66+6.1%$5.88+60.5%+221.6%$298.95M$15.41M-12.62180Upcoming EarningsAnalyst UpgradeACIUAC Immune3.1595 of 5 stars$2.97-1.3%$12.00+304.0%+1.7%$293.73M$15.49M-4.13140Short Interest ↓News CoveragePositive NewsGNFTGenfit1.5162 of 5 stars$5.85+6.2%$13.00+122.2%+94.8%$292.14M$76.06M0.00120Short Interest ↑News CoverageSTROSutro Biopharma4.079 of 5 stars$3.56+0.3%$12.13+240.6%+37.6%$291.19M$169.36M-1.95240Gap Up Related Companies and Tools Related Companies DSGN Competitors ITOS Competitors ACB Competitors QURE Competitors URGN Competitors RZLT Competitors PRQR Competitors ACIU Competitors GNFT Competitors STRO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INCR) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share InterCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INCR Stock Alerts